Tempest Therapeutics (TPST): CEO received 270K units

270K

Derivative units

Traded

Feb 4, 2026

Filed

Feb 6, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jan 8, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“As previously disclosed in Tempest Therapeutics, Inc.’s (the “Company’s”) definitive proxy statement on Schedule 14A, filed with the Securities and Exchange Commission on December 31, 2025, the Company has scheduled its 2025 Annual Meeting of Stockholders to be held on January 27, 2026 (the “2025 Annual Meeting”).”
2. Jan 27, 2026Company filing · Form 8-K · Shareholder rights, Executive changeChanged a top executive or board member, and changed the rights of its shareholders (and 1 more item)“On January 27, 2026, the Company’s stockholders approved Amendment No. 1 (the “ Plan Amendment ”) to the Company’s Amended and Restated 2023 Equity Incentive Plan (the “ 2023 EIP ”) to increase the number of shares of the Company’s common stock issuable under such plan by 1,410,000 shares.”
3. Feb 3, 2026Company filing · Form 8-K · Material agreement, Acquisition or saleCompleted buying or selling a business or assets, and control of the company changed hands (and 3 more items)“On February 3, 2026, immediately following the closing of the Asset Acquisition (the “ Closing ”), Geoff Nichol resigned from the Board, effective immediately. Mr. Nichol’s resignation was not because of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.”

What came next

1. Mar 20, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
2. Mar 24, 2026Insider · Bought outside the usual windowCEO purchased ~$500K of TPST shares in the open market
3. Mar 30, 2026Company filing · Form 8-K · ResultsReported its results
4. May 14, 2026Company filing · Form 8-K · ResultsReported its results
5. May 19, 2026Company filing · Form 8-K · Listing noticeReceived a notice from its stock exchange“On May 19, 2026, Tempest Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.”
6. May 22, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 22, 2026, each of Mr. Stephen Brady, Mr. Michael Raab and Ms. Christine Pellizzari notified Tempest Therapeutics, Inc. (the “Company”) of his or her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.”
7. May 23, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On May 23, 2026, Ms. Simantov notified Tempest Therapeutics, Inc. (the “Company”) of her resignation from the Board of Directors of the Company (the “Board”), effective as of such date.”
8. May 28, 2026Company filing · Form 8-K · Material agreement, Unregistered sharesSigned an important agreement, and sold new shares without registering them
9. May 29, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On May 29, 2026, Mr. Nicholas Maestas notified Tempest Therapeutics, Inc. (the “Company”) of his decision to resign from his position as Chief Financial Officer of the Company and from any and all other positions he holds with the Company, effective as of June 5, 2026.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Tempest Therapeutics

OQRO holds no insider, Congress, fund or contract record for Tempest Therapeutics dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its TPST page.

Other recent filings by Matthew Angel, CEO and President

• SEC Form 4 at Tempest Therapeutics (TPST)Mar 25, 2026

The full history of Matthew Angel, CEO and President is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Tempest Therapeutics

• SEC Form 4Mar 25, 2026

Everything OQRO holds on this company is on its TPST page.